Articles tagged "Immunosuppression"

2016 American Transplant Congress
Early Conversion to Everolimus in De Novo Renal Transplant Recipients: Incidence of Viral Infections in the Randomized-Controlled ELEVATE Study.
H. Hirsch,¹ J. De Fijter,¹ M. van der Giet,¹ M. Zeier,¹ J. Pascual,¹ Y. Avihingsanon,¹ P. Lopez,² J. Aguilar-Sanchez,² J. Kochuparampil,² Z. Wang,³ H. Holdaas,¹ J. Cruzado.¹
¹ELEVATE Study Group, Basel, Switzerland; ²Novartis, Basel, Switzerland; ³Novartis Pharmaceutical Corporation, East Hanover.
BackgroundCytomegalovirus (CMV) and BK polyomavirus (BKPyV) infections are independent risk factors for acute rejection and graft loss. Early conversion from calcineurin inhibitors (CNIs) to everolimus…
2016 American Transplant Congress
Everolimus versus Mycophenolate Mofetil in Combination with Tacrolimus: A Propensity Score Matching Analysis in Liver Transplantation.
P. de Simone,¹ P. Carrai,¹ A. Precisi,² L. Coletti,¹ D. Ghinolfi,¹ F. Filipponi.¹
¹Hepatobiliary Surgery and Liver Transplantation, University of Pisa Medical School Hospitals, Pisa, Italy; ²Laboratory, University of Pisa Medical School Hospital, Pisa, Italy.
Background: No trial has so far investigated everolimus (EVR)-incorporating immunosuppressive regimens versus combined use of tacrolimus (TAC) and mycophenolate mofetil (MMF) in liver transplantation (LT).Materials…
2016 American Transplant Congress
Blockade of HLA Antibody-Triggered Classical Complement Activation by High-Affinity Humanized Monoclonal Anti-C1s Antibody TNT009 – Results of a First-in-Human Phase 1 Trial.
J. Mühbacher,¹ B. Jilma,² M. Wahrmann,³ L. Marinova,³ F. Eskandary,³ J. Gilbert,⁴ S. Panicker,⁴ G. Böhmig.³
¹Department of Surgery, Medical University of Vienna, Vienna, Austria; ²Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria; ³Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria; ⁴True North Therapeutics, Inc., South San Francisco, CA.
Study purpose: Classical complement may play a key role in ABMR. A promising therapeutic approach could be complement inhibition at the level of key component…
2016 American Transplant Congress
Soluble Fibrinogen-Like Protein 2 Regulates Differentiation and Enhances Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Allograft Immunity.
C. Yang,^1,4 L. Wang,³ R. Rong,^2,4 T. Zhu,^2,4 M. Xu.^2,4
¹Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China; ²Urology, Zhongshan Hospital, Fudan University, Shanghai, China; ³Biomedical Research Center, Zhongshan Hospital, Fudan University, Shanghai, China; ⁴Shanghai Key Laboratory of Organ Transplantation, Shanghai, China.
Soluble fibrinogen-like protein 2 (sFGL2) is a novel immunoregulatory molecule, secreted mainly by regulatory T cells. CD11b+ Gr1+ myeloid-derived suppressor cells (MDSCs) are an important…
2016 American Transplant Congress
Monocytic TNF-α Response to EBV Peptides as a Mean to Identify Over-Immunosuppressed Kidney Transplant Recipients.
P. Vallin,¹ O. Désy,¹ S. Béland,¹ E. Wagner,² S. De Serres.¹
¹Renal Division, Quebec University Health Center, Laval University, Quebec, QC, Canada; ²Immunology and Histocompatibility Laboratory, Quebec University Health Center, Laval University, Quebec, QC, Canada.
Background. The reduction in acute rejection rates seen with the current triple immunosuppressive maintenance regimen has come at the expense of an increased risk of…
2016 American Transplant Congress
A Randomized-Controlled Trial Comparing the Efficacy of CYP3A5 Genotype-Based with Bodyweight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation.
N. Shuker,^1,2 R. Bouamar,² R. van Schaik,³ M. Clahsen -van Groningen,⁴ J. Damman,⁵ C. Baan,¹ J. van de Wetering,¹ A. Rowshani,¹ W. Weimar,¹ T. van Gelder,^1,2 D. Hesselink.¹
¹Internal Medicine, Erasmus Medical Centre, Rotterdam, Netherlands; ²Hospital Pharmacy, Erasmus Medical Centre, Rotterdam, Netherlands; ³Clinical Chemistry, Erasmus Medical Centre, Rotterdam, Netherlands; ⁴Pathology, Erasmus Medical Centre, Rotterdam, Netherlands; ⁵Pathology, Academic Medical Centre, Amsterdam, Amsterdam, Netherlands.
Patients expressing the cytochrome P450 (CYP) 3A5 gene require a higher tacrolimus dose to achieve therapeutic exposure compared with non-expressers. This randomized-controlled study investigated if…
2016 American Transplant Congress
Only 13% of Liver Transplant (LT) Recipients with Moderate to Severe Kidney Disease (KD) Tolerate Conversion to Everolimus and Reduced Tacrolimus (EVR/rTac).
S.-H. Pan, I. Kim, A. Klein, A. Annamalai, T. Todo, N. Nissen.
Liver Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.
EVR/rTac has been reported to improve renal function in LT recipients with adequate kidney function (eGFR > 80ml/min); however, this strategy in LT patients with…
2016 American Transplant Congress
Preimplantation and Post-Transplant Serial Biopsies of Standard and Extended Criteria Donor Kidneys: Intragraft Molecular Profiles and Effect of Different Immunosuppressive Protocols.
C. Mazeti,¹ H. Caldas,¹ I. Fernandes-Charpiot,² M. Baptista,² M. Abbud-Filho.^1,2,3
¹Laboratory of Immunology and Experimental Transplantation, Medical School, Sao Jose do Rio Preto, SP, Brazil; ²Department of Medicine/Nephrology, Medical School, Sao Jose do Rio Preto, SP, Brazil; ³Urology and Nephrology Institute, Urology and Nephrology Institute, Sao Jose do Rio Preto, SP, Brazil.
Background: Use of extended criteria donor kidneys (ECD) carries the fear of to transplant of inferior quality and therefore of high discard rate. Clinical tools…
2016 American Transplant Congress
Pneumocystis Pneumonia Following Solid Organ Transplantation, Systematic Review and Meta-Analysis.
S. Hosseini-Moghaddam,^1,2 R. Krishnan.²
¹Medicine, Western University, London, ON, Canada; ²Epidemiology and Biostatistics, Western University, London, ON, Canada.
Background: Different variables have been reported that may increase the risk of pneumocystis pneumonia (PCP) in solid organ transplant patients (SOT).Objectives:To investigate the effect of…
2016 American Transplant Congress
Quality Improvement Initiative to Provide Comprehensive Pharmacy Services to Kidney Transplant Patients at a Small Transplant Center.
J. Dickson,¹ W. Vincent III,¹ L. Wu,² J. Thurman,¹ J. Francis,³ M. Nuhn.⁴
¹Pharmacy, Boston Medical Center, Boston, MA; ²Northeastern University, Boston, MA; ³Renal Medicine, Boston Medical Center, Boston, MA; ⁴Transplant Surgery, Boston Medical Center, Boston, MA.
Purpose: Previously, kidney transplant pharmacy services at our institution were limited to medication profile review before and after transplant surgery. Following an OPTN accreditation site…